Compugen (CGEN)
(Delayed Data from NSDQ)
$1.48 USD
+0.03 (2.07%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.46 -0.02 (-1.35%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CGEN 1.48 +0.03(2.07%)
Will CGEN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEN
Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?
CGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?
Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength?
Other News for CGEN
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian ...
Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025 | CGEN Stock News
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive ...
Compugen (CGEN) Advances with Key Ovarian Cancer Trial | CGEN Stock News
Compugen begins dosing in ovarian cancer trial